Tiotropium as a first maintenance drug in COPD: Secondary analysis of the UPLIFT® trial

European Respiratory Journal

Volumn 36, Issue 1, 2010, Pages 65-73

  Troosters, T ^a   Celli, B ^b   Lystig, T ^c   Kesten, S ^c   Mehra, S ^d   Tashkin, D P ^e   Decramer, M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d PFIZER INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticholinergic agent; Chronic obstructive pulmonary disease; Disease progression; Exacerbation; Lung function; Quality of life

Indexed keywords

PLACEBO; TIOTROPIUM BROMIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; SCOPOLAMINE DERIVATIVE; THEOPHYLLINE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPIROMETRY; SURVIVAL RATE; TREATMENT OUTCOME; AGED; DRUG EFFECTS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AGED; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SCOPOLAMINE DERIVATIVES; SPIROMETRY; THEOPHYLLINE; TIME;

EID: 77954650588     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00127809     Document Type: Article

References (25)

1. Pelkonen M, Notkola IL, Nissinen A, et al. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest 2006; 130: 1129-1137. (Pubitemid 44583744)
2. van Durme YM, Verhamme KM, Stijnen T, et al. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest 2009; 135: 368-377.
3. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555. (Pubitemid 47403272)
4. TashkinDP,Celli B, Senn S, et al. A4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
5. Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 948-955.
6. Decramer M, Celli BR, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the "Uplift" trial. COPD 2004; 1: 151-160.
7. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
8. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 5-40.
9. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-1136.
10. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-974.
11. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 842-846.
12. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
13. Tashkin DP, Celli B, Kesten S, et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2010; 35: 287-294.
14. Suissa S. Lung function decline in COPD trials: bias from regression to the mean. Eur Respir J 2008; 32: 829-831.
15. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-1178.
16. Celli B, Kesten S, Lystig T, et al. COPDpatients under 50 years of age: 4-year follow-up in theUPLIFT trial.EurRespir J 2009; 34: Suppl. 53, 674s.
17. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary diesease, a meta-analysis. Thorax 2006; 61: 854-862. (Pubitemid 44570305)
18. Sin DD, McAlister FA, Man SF, et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003; 290: 2301-2312. (Pubitemid 37430563)
19. Spencer S, Calverley PM, Sherwood BP, et al. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 122-128. (Pubitemid 32095261)
20. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS). Lancet 2005; 365: 1552-1560.
21. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone proprionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789. (Pubitemid 46294610)
22. Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 972-977. (Pubitemid 40616945)
23. Watz HB, Waschki C, Boehme M, et al. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity. Am J Respir Crit Care Med. 2008; 177: 743-751.
24. Pitta F, Troosters T, Probst V, et al. Are patients with COPD more active after pulmonary rehabilitation? Chest 2008; 134: 273-280.
25. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005; 365: 176-186.